Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jul 26 04:00PM ET
9.24
Dollar change
-0.09
Percentage change
-0.96
%
IndexRUT P/E- EPS (ttm)-0.49 Insider Own5.58% Shs Outstand43.12M Perf Week1.32%
Market Cap403.79M Forward P/E103.44 EPS next Y0.09 Insider Trans-4.62% Shs Float41.26M Perf Month23.20%
Income-21.28M PEG- EPS next Q-0.07 Inst Own80.39% Short Float5.91% Perf Quarter41.72%
Sales163.73M P/S2.47 EPS this Y-9.16% Inst Trans4.16% Short Ratio7.31 Perf Half Y-2.84%
Book/sh2.13 P/B4.33 EPS next Y148.14% ROA-11.32% Short Interest2.44M Perf Year5.24%
Cash/sh0.54 P/C17.09 EPS next 5Y- ROE-22.32% 52W Range3.45 - 10.83 Perf YTD35.29%
Dividend Est.- P/FCF- EPS past 5Y3.44% ROI-13.24% 52W High-14.70% Beta1.06
Dividend TTM- Quick Ratio2.23 Sales past 5Y13.87% Gross Margin79.73% 52W Low167.83% ATR (14)0.47
Dividend Ex-DateJan 27, 2010 Current Ratio3.43 EPS Y/Y TTM14.89% Oper. Margin-11.41% RSI (14)66.02 Volatility5.51% 5.78%
Employees428 Debt/Eq0.74 Sales Y/Y TTM13.51% Profit Margin-13.00% Recom1.14 Target Price12.71
Option/ShortYes / Yes LT Debt/Eq0.72 EPS Q/Q7.64% Payout- Rel Volume0.53 Prev Close9.33
Sales Surprise-1.38% EPS Surprise11.76% Sales Q/Q12.86% EarningsAug 08 BMO Avg Volume333.70K Price9.24
SMA2010.55% SMA5024.22% SMA20026.93% Trades Volume178,133 Change-0.96%
Date Action Analyst Rating Change Price Target Change
Jul-01-24Initiated Raymond James Outperform $13
Nov-11-22Resumed Jefferies Buy $15
May-09-22Upgrade Canaccord Genuity Hold → Buy $10 → $15
Mar-11-22Resumed Cantor Fitzgerald Overweight $21
Oct-23-20Initiated Guggenheim Buy $24
Jun-16-20Resumed Cantor Fitzgerald Overweight $16
May-07-20Downgrade Canaccord Genuity Buy → Hold $12
Apr-02-20Downgrade BTIG Research Buy → Neutral
Aug-07-19Downgrade William Blair Outperform → Mkt Perform
Jul-12-19Initiated Canaccord Genuity Buy $32
Jul-23-24 07:00AM
Jul-12-24 08:37AM
Jul-01-24 07:00AM
Jun-25-24 12:52PM
Jun-24-24 07:00AM
04:56AM Loading…
Jun-12-24 04:56AM
May-28-24 04:30PM
May-17-24 12:29PM
May-16-24 02:56PM
07:00AM
May-14-24 07:00AM
May-06-24 10:31AM
May-03-24 03:02AM
May-02-24 11:57AM
08:15AM
07:14AM Loading…
07:14AM
07:00AM
Apr-29-24 04:50PM
Apr-16-24 07:00AM
Mar-08-24 11:55PM
Mar-06-24 08:20AM
Mar-05-24 09:27PM
11:53AM
07:38AM
07:31AM
07:00AM
Feb-28-24 08:50AM
Feb-26-24 09:15AM
Feb-13-24 04:30PM
Feb-12-24 08:50AM
09:40AM Loading…
Feb-06-24 09:40AM
Feb-02-24 04:15PM
Jan-26-24 08:50AM
Jan-18-24 05:00PM
Jan-04-24 04:45PM
04:40PM
04:35PM
Dec-26-23 04:15PM
Dec-06-23 07:00AM
Dec-01-23 05:00PM
Nov-20-23 07:00AM
Nov-08-23 09:41AM
Nov-07-23 11:01PM
08:04AM
07:15AM
07:00AM
Nov-02-23 10:00AM
Oct-31-23 10:01AM
Oct-18-23 07:00AM
Oct-16-23 10:23AM
Sep-28-23 08:21AM
Sep-05-23 07:00AM
Aug-31-23 07:00AM
Aug-21-23 07:00AM
Aug-10-23 03:03PM
12:05PM
Aug-08-23 10:59AM
05:57AM
Aug-07-23 05:25PM
04:18PM
04:01PM
Aug-03-23 05:55PM
Jul-27-23 07:00AM
Jul-26-23 07:00AM
Jun-10-23 10:42AM
Jun-09-23 09:55AM
May-24-23 07:00AM
May-12-23 07:00AM
May-09-23 08:35AM
07:34AM
07:00AM
Apr-18-23 04:05PM
07:25AM
Mar-17-23 04:31AM
Mar-16-23 06:30AM
Mar-14-23 11:23PM
07:00AM
Mar-06-23 07:00AM
Mar-02-23 04:00PM
Mar-01-23 09:21AM
Feb-13-23 07:00AM
Jan-09-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Jan-01-23 08:52AM
Dec-19-22 07:00AM
Nov-11-22 08:50AM
Nov-08-22 08:15AM
08:00AM
07:00AM
Nov-03-22 04:00PM
Oct-31-22 07:00AM
Oct-27-22 12:00PM
Oct-20-22 07:00AM
Oct-19-22 09:40AM
Sep-29-22 05:32AM
Sep-22-22 09:55AM
07:00AM
Aug-08-22 09:55AM
09:40AM
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm's products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Freitag Gregory GeneDirectorJun 04 '24Option Exercise0.0011,9040283,498Jun 06 04:49 PM
Scopelianos AngeloChief R&D OfficerMar 21 '24Option Exercise0.002,500058,604Mar 25 09:37 PM
Zaderej Karen L.CEOMar 21 '24Sale7.6839,280301,6701,124,565Mar 25 09:43 PM
Scopelianos AngeloChief R&D OfficerMar 21 '24Sale7.686,88152,84652,999Mar 25 09:37 PM
Donovan Michael PatrickVP OperationsMar 21 '24Sale7.686,03346,33337,992Mar 25 09:22 PM
DeVinney Erick WayneChief Innovation OfficerMar 21 '24Sale7.684,57835,159165,661Mar 25 09:40 PM
Zaderej Karen L.CEOMar 16 '24Option Exercise0.00110,32201,157,593Mar 25 09:43 PM
DeVinney Erick WayneChief Innovation OfficerMar 16 '24Option Exercise0.0018,6750180,615Mar 25 09:40 PM
Scopelianos AngeloChief R&D OfficerMar 16 '24Option Exercise0.0025,406058,250Mar 25 09:37 PM
Donovan Michael PatrickVP OperationsMar 16 '24Option Exercise0.0024,575058,846Mar 25 09:22 PM
Donovan Michael PatrickVP OperationsMar 07 '24Sale8.8136,310319,89135,708Mar 08 05:33 PM
Freitag Gregory GeneDirectorMar 07 '24Sale9.0025,000225,000271,594Mar 08 05:31 PM
MARIANI PETER JEVP & Chief Financial OfficerDec 11 '23Sale7.5012,50093,80963,603Dec 13 04:07 PM
Wendell Amy McBrideDirectorSep 06 '23Buy6.2210,00062,24080,342Sep 08 04:20 PM
Burke William P. Mr.DirectorAug 23 '23Buy6.5610,00065,60010,000Aug 25 04:16 PM
NEELS GUIDO JDirectorAug 16 '23Buy6.1110,00061,10068,259Aug 18 04:12 PM